Stock AELIS AELIS FARMA
Add to a list
To use this feature you must be a member
Log inSign up

News Aelis Farma

Equities

AELIS

FR0014007ZB4

Real-time Euronext Paris
Other stock markets
 04:33:12 29/04/2024 pm IST 		5-day change 1st Jan Change
13.1 EUR +0.77% Intraday chart for Aelis Farma 0.00% 0.00%
18/04 Aelis Farma SA Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder CI
02/04 Aelis Farma SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aelis Farma: Availability of the 2023 Universal Registration Document
BU
Aelis Farma Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder
BU
Aelis Farma SA Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder
CI
Aelis Farma Reports Its 2023 Annual Financial Resultsand Confirms Its 2024 Outlook
BU
Aelis Farma SA Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aelis Farma Appoints Chief Corporate Development Officer
MT
Aelis Farma Announces the Appointment of Arsène Guekam as Chief Corporate Development Officer
CI
Aelis Farma Announces Completion of Patient Randomization for Phase 2B Study with Aef0117 for the Treatment of Cannabis Addiction
CI
Aelis Farma Announces Positive Results of Non-Clinical Studies Required by Regulatory Agencies to Enter Its First Cb1-SSI, AEF0117, in Phase 3 Clinical Trial for the Treatment of Cannabis Use Disorder
CI
Aelis Farma SA Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Aelis Farma: CEO and co-founder recognized by his peers
CF
Aelis Farma : Inside Information / Other news releases
PU
Data Safety Monitoring Board OKs Aelis Farma's Mid-stage Trial of Cannabis Addiction Drug
MT
Aelis Farma: received a positive opinion from the DSMB
CF
Aelis Farma Receives a Positive Recommendation From the DSMB to Continue, With No Modification to the Protocol, the Phase 2b Clinical Study With AEF0117 in Cannabis Addiction
CI
Aelis Farma: favorable preclinical data in autism
CF
Aelis Farma Announces the Presentation of New Preclinical Data on its Drug Candidate AEF0217 at the 2nd European Conference on Phelan-McDermid Syndrome
CI
CAC40: ends in green, ignores eurozone recession
CF
Aelis Farma: promising results for AEF0117
CF
Aelis Farma SA Approves Transfer of Registered Office
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AELIS Stock
  4. News Aelis Farma